POP Treatment and Management / Pelvic Organ Prolapse Market by Product (Synthetic Mesh, Sutures, Pessaries, Robotic Systems), Treatment (Surgical, PFMT), Application (Cystocele, Uterine Prolapse), End User (Hospitals, ASCs), Region - Global Forecast to 20

The global POP Treatment and Management / Pelvic Organ Prolapse market is projected to reach USD 1.06 billion by 2030 from USD 0.77 billion in 2025, at a CAGR of 6.6% during the forecast period.

The market is expected to witness high growth due to the high global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques. Complications and recalls associated with vaginal mesh, limited access and affordability in developing markets, underdiagnosis due to social stigma, and the risk of POP products are likely to restrain market growth.

“The hospitals segment of the POP Treatment and Management / Pelvic Organ Prolapse market, by end user, is expected to hold the largest position during the forecast period.”

Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory surgery centers (ASCs), and others. In 2024, hospitals and clinics accounted for the largest share of the market. Hospitals benefit from centralized procurement systems, allowing for efficient integration of new POP technologies. Their access to government or institutional funding also facilitates the acquisition of expensive devices, such as robotic surgical systems, which may not be feasible in smaller outpatient facilities. Furthermore, hospitals are often the only facilities equipped to manage intraoperative complications, complex reconstructions, and comorbid conditions in elderly patients—ensuring their continued dominance in the pelvic organ prolapse treatment landscape.

“The surgical segment accounted for the larger market share in the POP Treatment and Management / Pelvic Organ Prolapse market.”

The POP Treatment and Management / Pelvic Organ Prolapse market is segmented into surgical and non-surgical. The surgical segment accounted for the larger share of the market in 2024. Surgical intervention is often preferred in cases involving multiple-compartment prolapses or associated conditions like stress urinary incontinence. Moreover, with the growing availability of minimally invasive and robotic-assisted methods, surgical options now offer quicker recovery and reduced postoperative complications, making them more acceptable to both patients and clinicians. Continuous innovation in surgical meshes, biologic grafts, and energy-assisted dissection tools further enhances procedural outcomes. Importantly, surgical treatments are backed by strong clinical guidelines and are often the first-line recommendation in moderate to severe POP, reinforcing their dominant position in the market.

“Asia Pacific is the fastest-growing market for POP Treatment and Management / Pelvic Organ Prolapse.”

The global POP Treatment and Management / Pelvic Organ Prolapse market is segmented into five segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is experiencing rapid population aging, especially in countries like China and Japan, leading to a rising incidence of pelvic organ prolapse disorders among elderly women. Increasing awareness of women’s health and growing acceptance of pelvic floor treatments are driving higher diagnosis and treatment rates. Governments across the region are investing in healthcare infrastructure, expanding access to surgical facilities, and supporting the adoption of advanced medical technologies, including robotic-assisted procedures. The rise of medical tourism in countries such as India and South Korea further fuels market growth, offering high-quality care at lower costs. While access disparities and a shortage of trained specialists still exist in rural areas, ongoing investments in healthcare training, digital health platforms, and public awareness campaigns are helping to close these gaps, positioning Asia Pacific as the fastest-growing regional market.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
• By Designation: C Level: 27%, Director Level: 18%, and Others: 55%
• By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 =

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the POP Treatment and Management / Pelvic Organ Prolapse market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), and Johnson & Johnson (US).

Research Coverage

This report studies the POP Treatment and Management / Pelvic Organ Prolapse market based on product, treatment, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them to garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

This report provides insights into the following pointers:

Analysis of key drivers (High global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques), restraints (complications and recalls associated with vaginal mesh, limited access and affordability in developing market, and underdiagnosis due to social stigma), opportunities (growth opportunities in emerging economies, development of bioengineered and absorbable mesh and digital health and pelvic floor therapy devices), and challenges (inconsistent clinical guidelines and treatment standards, and high recurrence and reoperation rates)

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the POP Treatment and Management / Pelvic Organ Prolapse market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the POP Treatment and Management / Pelvic Organ Prolapse market

Market Development: Comprehensive information on lucrative emerging regions

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the POP Treatment and Management / Pelvic Organ Prolapse market

Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players Show more